Literature DB >> 30067107

Global epidemiology of viral hepatitis and national needs for complete control.

Simone Lanini1, Raffaella Pisapia1, Maria Rosaria Capobianchi1, Giuseppe Ippolito1.   

Abstract

INTRODUCTION: The World Health Organization recognizes that viral hepatitis is not only a massive public health issue but also a huge opportunity to improve quality of life and equity at a global level. Viral hepatitis causes about 1.5 million deaths each year and significantly affects the quality of life of hundreds of millions of people. To date, frail individuals in high-income countries and people living in low-income settings are paying the heaviest tool. Areas covered. Here we present a broad discussion on current knowledge and topical issues about the hepatitis pandemic. The report includes a structured overview of global epidemiology, including the definition of specific local epidemic profiles for each hepatitis agents (HAV, HBV, HCV, and HEV), and a perspective about the critical actions needed for achieving a complete control. Expert commentary. The control of viral hepatitis is currently, ethically urgent and even economically convenient. There is a wide consensus that viral hepatitis can be controlled through comprehensive intervention tailored on local needs addressing the issue of viral hepatitis as a unique public health issue. These strategies should include: (1) primary prevention (including vaccination and improved infection control), (2) improving diagnosis rate, and (3) management of existing cases of infections.

Entities:  

Keywords:  Viral hepatitis; disease control; epidemic control; epidemiology; infection elimination; infection eradication

Mesh:

Substances:

Year:  2018        PMID: 30067107     DOI: 10.1080/14787210.2018.1505503

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  6 in total

1.  Hepatitis B and Hepatitis C Virus Infection Promote Liver Fibrogenesis through a TGF-β1-Induced OCT4/Nanog Pathway.

Authors:  Wenting Li; Xiaoqiong Duan; Chuanlong Zhu; Xiao Liu; Andre J Jeyarajan; Min Xu; Zeng Tu; Qiuju Sheng; Dong Chen; Chuanwu Zhu; Tuo Shao; Zhimeng Cheng; Shadi Salloum; Esperance A Schaefer; Annie J Kruger; Jacinta A Holmes; Raymond T Chung; Wenyu Lin
Journal:  J Immunol       Date:  2022-01-12       Impact factor: 5.422

2.  Associations between polymorphisms in IL-10 gene and the risk of viral hepatitis: a meta-analysis.

Authors:  Yuanyuan Zhang; Lisha Chen; Huixin Chen
Journal:  Gut Pathog       Date:  2020-07-28       Impact factor: 4.181

3.  Relationship of genetic polymorphisms in CTLA-4 and IL-18 with viral hepatitis: evidence from a meta-analysis.

Authors:  Yang Yu; Jie Qu; Chen Zhou; Guangqiang You
Journal:  Epidemiol Infect       Date:  2019-12-05       Impact factor: 2.451

Review 4.  Management of Diabetes Mellitus in Patients with Chronic Liver Diseases.

Authors:  Yingying Zhao; Huichun Xing; Xiaomei Wang; Weini Ou; Hong Zhao; Ben Li; Yue Li; Ying Duan; Liwei Zhuang; Wei Li; Danying Cheng; Min Quan; Yu Zhang; Shibo Ji
Journal:  J Diabetes Res       Date:  2019-12-14       Impact factor: 4.011

Review 5.  Emerging role and therapeutic application of exosome in hepatitis virus infection and associated diseases.

Authors:  Ying Shi; Lingyao Du; Duoduo Lv; Yan Li; Zilong Zhang; Xiaolun Huang; Hong Tang
Journal:  J Gastroenterol       Date:  2021-03-04       Impact factor: 7.527

Review 6.  Liver, Tumor and Viral Hepatitis: Key Players in the Complex Balance Between Tolerance and Immune Activation.

Authors:  Matti Sällberg; Anna Pasetto
Journal:  Front Immunol       Date:  2020-03-27       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.